| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Dehydroandrographolide succinate potassium sodium salt targets inflammatory and immune pathways, exhibiting immunostimulatory effects by enhancing immune function, and anti-infective activity against viral and bacterial pathogens; it is used for the treatment of viral pneumonia and upper respiratory tract infections.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Dehydroandrographolide succinate potassium sodium salt exhibits anti-inflammatory effects by modulating immune responses, and shows activity against viruses and bacteria, supporting its use as an anti-infective agent.
|
| ln Vivo |
In vivo, Dehydroandrographolide succinate potassium sodium salt has been used clinically for the treatment of viral pneumonia and viral upper respiratory tract infections, demonstrating immunostimulatory and anti-inflammatory effects in patients.
|
| Enzyme Assay |
The in vitro anti-inflammatory assay involves treating immune cells (e.g., macrophages) with Dehydroandrographolide succinate potassium sodium salt and stimulating with LPS or other inflammatory triggers, measuring cytokine production (TNF-α, IL-6, IL-1β) by ELISA, and assessing NF-κB activation by reporter gene assays or Western blotting.
|
| Cell Assay |
In vitro antiviral assays utilize virus-infected cell lines (e.g., influenza virus-infected MDCK cells) treated with the compound, measuring viral replication by plaque reduction assays or by quantifying viral RNA by RT-qPCR, with IC50 values calculated from inhibition curves.
|
| Animal Protocol |
In vivo animal experiments for evaluating antiviral and immunostimulatory effects involve administering the compound to virus-infected animal models (e.g., influenza-infected mice), measuring viral load in lungs, assessing inflammatory cytokine levels, and evaluating survival outcomes and lung pathology.
|
| ADME/Pharmacokinetics |
Dehydroandrographolide succinate potassium sodium salt has a molecular formula C28H36O10•K•Na and molecular weight 594.67 g/mol; it is a water-soluble salt form, typically stored as a solid powder at room temperature, and is formulated for parenteral administration in clinical use.
|
| Toxicity/Toxicokinetics |
Toxicological data indicate that Dehydroandrographolide succinate potassium sodium salt is generally well-tolerated in clinical use, with mild adverse effects including gastrointestinal disturbances and allergic reactions; it is contraindicated in patients with known hypersensitivity to andrographolide derivatives.
|
| References |
|
| Additional Infomation |
Dehydroandrographolide succinate potassium sodium salt (Yanhuning) is an approved pharmaceutical agent in China for the treatment of viral pneumonia and upper respiratory tract infections; it is available as an injectable formulation and is used in combination with other antiviral or anti-inflammatory agents for the management of viral infections.
|
| Molecular Formula |
C28H34KNAO10
|
|---|---|
| Molecular Weight |
592.6516
|
| Exact Mass |
592.169
|
| CAS # |
863319-40-8
|
| Related CAS # |
786593-06-4(free acid);76958-99-1 (Kalii Dehydrographolidi Succinas);
|
| PubChem CID |
72941925
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.277
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
40
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@]12[C@H](/C=C/C3=CCOC3=O)C(=C)CC[C@@H]1[C@]([C@@H](CC2)OC(=O)CCC(=O)O)(C)COC(=O)CCC(=O)O.[K].[Na]
|
| InChi Key |
MZXSMTFMRXUGGI-RYVVASIESA-L
|
| InChi Code |
InChI=1S/C28H36O10.K.Na/c1-17-4-7-20-27(2,19(17)6-5-18-13-15-36-26(18)35)14-12-21(38-25(34)11-9-23(31)32)28(20,3)16-37-24(33)10-8-22(29)30;;/h5,13,15,19-21H,1,4,6-12,14,16H2,2-3H3,(H,29,30)(H,31,32);;/q;2*+1/p-2/b18-5+;;/t19-,20+,21-,27+,28+;;/m1../s1
|
| Chemical Name |
potassium;sodium;4-[[(1R,2R,4aS,5R,8aS)-2-(3-carboxylatopropanoyloxy)-1,4a-dimethyl-6-methylidene-5-[(2E)-2-(2-oxofuran-3-ylidene)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-4-oxobutanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6873 mL | 8.4367 mL | 16.8734 mL | |
| 5 mM | 0.3375 mL | 1.6873 mL | 3.3747 mL | |
| 10 mM | 0.1687 mL | 0.8437 mL | 1.6873 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
